Content area
Abstract
ECHELON-1 trial Joseph M Connors (British Columbia Cancer Agency, Vancouver, BC, Canada) reported the findings from ECHELON-1, an open-label, randomised, multicentre, phase 3 trial of A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as first-line therapy for 1334 patients with previously untreated advanced Hodgkin's lymphoma. ADCT-402 The interim results of a first-in-human, phase 1 study of ADCT-402 (loncastuximab tesirine; a humanised anti-CD19 antibody conjugated to a pyrrolobenzodiazepine toxin) in 80 patients with relapsed or refractory B-cell lineage non-Hodgkin lymphoma were reported by Brad S Kahl (Washington University School of Medicine, Saint Louis, MO, USA). Molecular MRD in AML Tim Grob (Erasmus University Medical Center, Rotterdam, Netherlands) presented results of a study to detect molecular minimal residual disease (MRD) with next-generation sequencing (NGS) in a prospective cohort of 482 patients with newly diagnosed acute myeloid leukaemia.